Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

CTI Announces Acquisition of Community Research

Published: Friday, February 07, 2014
Last Updated: Friday, February 07, 2014
Bookmark and Share
Company adds three locations and expands service offerings.

CTI Clinical Trial and Consulting Services (CTI) has announced the acquisition of Community Research.

Community Research is a dedicated, multi-specialty clinical research site with three locations throughout Greater Cincinnati, Ohio. Community Research conducts 40-60 phase I-IV clinical trials annually in a variety of therapeutic indications, including internal medicine, dermatology, psychiatry, and sleep disorders, as well as trials in healthy volunteers.

Community Research operates a hospital-based, residential phase I facility, which can accommodate drug and device trials, and has a special emphasis on first-in-human studies in various patient populations. Since its inception nearly 20 years ago, Community Research has completed over 650 clinical trials.

David Mayleben, PhD, President and Co-Founder of Community Research, will become a Vice President at CTI, and will continue to lead the research centers, while Co-Founder, Dr. Bruce Corser, will serve as a consultant for CTI, but will not be involved in day-to-day activities. The team of over 50 employees from Community Research will also be joining CTI.

“This is a great opportunity to strengthen the offerings that Community Research provides to those in the pharmaceutical and biotechnology industries,” according to David Mayleben, Co-Founder and President of Community Research. “We have worked with CTI many times over the past several years and are excited for this new endeavor.”

“We are looking forward to the integration of both companies and adding the strong operational expertise Community Research has to our own organization,” according to Kevin Schwarz, Chief Operating Officer of CTI. “We feel that Community Research provides us with even greater service offerings for our clients, who include more than 70 pharmaceutical and biotechnology companies around the world.”

According to Timothy Schroeder, CEO and Founder of CTI, “This new addition will be particularly important with the increasing number of early stage trials that we are working on. Some of the most groundbreaking research is being done in phase I units for areas such as rare diseases, regenerative medicine, and oncology. This type of research will only increase in its importance in the next several years.”

The terms of the acquisition were not disclosed. Plante Moran and Fifth Third Bank provided support to CTI, while DeVita Howe, LLP, Edgemont Capital Partners, and JD Cloud assisted Community Research.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Genetic Defences of Bacteria Don’t Aid Antibiotic Resistance
Genetic responses to the stresses caused by antibiotics don’t help bacteria to evolve a resistance to the medications, according to a new study by Oxford University researchers.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Snapshot Turns T Cell Immunology on its Head
New research may have implications for 1 diabetes sufferers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
Horse Illness Shares Signs of Human Disease
Horses with a rare nerve condition have similar signs of disease as people with conditions such as Alzheimer’s, a study has found.
How a Molecular Motor Untangles Protein
Diseases such as Alzheimer’s, Parkinson’s and prion diseases, all involve “tangled” proteins.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos